TC-1698 explained

TC-1698 is a drug developed by Targacept which acts as a partial agonist for the α7 subtype of neural nicotinic acetylcholine receptors.^[1] It has neuroprotective effects in animal studies,^[2] and has been used as a lead compound to find further potent derivatives.^[3]

See also

• Anabasine

Notes and References

1. Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F . Central nicotinic receptors: structure, function, ligands, and therapeutic potential . ChemMedChem . 2 . 6 . 746–67 . June 2007 . 17295372 . 10.1002/cmdc.200600207 . 34763474 .
2. Marrero MB, Papke RL, Bhatti BS, Shaw S, Bencherif M . The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase . The Journal of Pharmacology and Experimental Therapeutics . 309 . 1 . 16–27 . April 2004 . 14722323 . 10.1124/jpet.103.061655 . 7730290 . 10.1.1.420.2457 .
3. Bhatti BS, Strachan JP, Breining SR, Miller CH, Tahiri P, Crooks PA, Deo N, Day CS, Caldwell WS . 6 . Synthesis of 2-(pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(pyridin-3-yl)-1-azabicyclo[2.2.2]octane, and 2-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a class of potent nicotinic acetylcholine receptor-ligands . The Journal of Organic Chemistry . 73 . 9 . 3497–507 . May 2008 . 18363376 . 10.1021/jo800028q .